Purpose of this Study
You will be randomly assigned to one of two study arms:
• Arm A: Sonrotoclax + Zanubrutinib
• Arm B: Venetoclax + Acalabrutinib
The study includes Screening (up to 35 days), Study Treatment, and Follow‑up. Screening involves exams, blood tests, heart tests, and imaging. Treatment includes oral medications with ramp‑up dosing schedules and regular monitoring.
Who Can Participate?
Eligibility
People can join this study if they are 18 years or older and have a confirmed diagnosis of CLL. They must have organs that are working well and complete the required health checks before joining. If they can become pregnant, they must have a negative pregnancy test and agree to use birth control during the study.
Age Range
18-100
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is comparing two pairs of cancer medicines to see which one works better for treating CLL. One pair is sonrotoclax and zanubrutinib. The other pair is venetoclax and acalabrutinib. The study is open label, which means you and your doctor will know which medicines you are getting.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Principal Investigator
Andrea
Sitlinger
Protocol Number
PRO00119487
NCT ID
NCT07277231
Phase
III
Enrollment Status
Pending Open to Enrollment